Eisai's Breast-Cancer Drug Rejected By UK's NICE
This article was originally published in PharmAsia News
Executive Summary
Eisai's launch of its breast-cancer drug Halaven (eribulin) in the UK was countered by the National Institute for Health and Clinical Excellence